Back to all Programs

Register here

Related Materials

Past event

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Viral Hepatitis and Liver Disease

Clinical Implications of Cabotegravir Plasma Levels - Charles Flexner, MD

Viral Hepatitis and Liver Disease

DDIs Relevant for COVID-19 Therapeutic Agents & Implementation Challenges - Fiona Marra, MPharm, MSc

Viral Hepatitis and Liver Disease

Emerging Strategies for Treating and Preventing Monkeypox 2022 - Ruth Byrne, MD

Viral Hepatitis and Liver Disease

Long-acting Cabotegravir Pharmacokinetics With and Without Oral Lead-in for HIV PrEP - Kelong Han

Viral Hepatitis and Liver Disease

The Non-adherent Patient A Good or Bad Candidate for CAB+RPV - Jose Castillo-Mancilla, MD

Viral Hepatitis and Liver Disease

CabotegravirRilpivirine Failures Despite Adherence Slides - Jose Castillo-Mancilla, MD

Viral Hepatitis and Liver Disease

Deep Learning Ensemble Classifier to Predict Drug-Drug Interaction - Thao Pham

Viral Hepatitis and Liver Disease

Islatravir Toxicity Slides - Charles Flexner, MD

Viral Hepatitis and Liver Disease

Lenacapavir Considerations - Jonathan Schapiro, MD

Viral Hepatitis and Liver Disease

Optimization of Pharmacology Studies and DDIs in Pregnant and Lactating Individuals - Angela Colbers, PhD

Viral Hepatitis and Liver Disease

Pharmacology Pearls for Managing Absorption and Swallowing Difficulties - Saye Khoo, MD, PhD

Viral Hepatitis and Liver Disease

Strategies to Improve Delivery to Reservoirs as Targets for Long-Acting Antivirals - Adeniyi Olagunju, BPharm, MRes, PhD